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Abstract: 
Phosphomevalonate kinase (PMK) phosphorylates mevalonate-5-
phosphate (M5P) in the mevalonate pathway, which is the sole source of 
isoprenoids and steroids in humans. We have identified new PMK inhibitors 
with virtual screening, using Autodock. Promising hits were verified and their 
affinity measured using NMR-based 1H-15N Heteronuclear Single Quantum 
Coherence (HSQC) chemical shift perturbation and fluorescence titrations. 
Chemical shift changes were monitored, plotted, and fitted to obtain 
dissociation constants (Kd). Tight binding compounds with Kd’s ranging from 
6–60 µM were identified. These compounds tended to have significant polarity 
and negative charge, similar to the natural substrates (M5P and ATP). HSQC 
crosspeak changes suggest that binding induces a global conformational 
change, such as domain closure. Compounds identified in this study serve as 
chemical genetic probes of human PMK, to explore pharmacology of the 
mevalonate pathway, as well as starting points for further drug development.  
Keywords: Human phosphomevalonate kinase, inhibitors, virtual screening, 
molecular docking. 
Introduction 
Phosphomevalonate kinase (PMK), a mevalonate pathway 
enzyme, catalyzes a key phosphorylation step in isoprenoid/sterol 
biosynthesis, and provides a variety of products that are necessary for 
normal cellular growth and signaling, such as cholesterol, bile acids, 
heme A, dolichol, and ubiquinone.[1] Due to the central role of 
isoprenoids, imbalances in isoprenoid synthesis and utilization can lead 
to cellular dysfunction and disease. [2–4] Inhibitors of two enzymes in 
this pathway are of particular clinical relevance. The statins, a large 
class of hydroxymethyl glutaryl-CoA reductase (HMG CoA) inhibitors, 
are widely used to treat elevated cholesterol levels.[5] And, 
bisphosphonate inhibitors of farnesylpyrophosphate synthase are used 
to treat metabolic bone disease.[6] However, the mechanism and 
pharmacology of other potentially druggable enzyme targets in this 
pathway are less well-characterized, so additional studies and 
pharmacological probes are needed.[7] 
PMK in comprised of two domains. The larger ATP-binding 
domain (CORE, Fig. 1) is composed of a five stranded parallel β-sheet 
interweaved with three α-helices. The mevalonate- 5-phosphate (M5P) 
domain (Substrate, Fig. 1) is composed of loop regions and two-α-
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helices. PMK catalyzes the transfer of a phosphoryl group from 
adenosine-5'-triphosphate (ATP) to M5P, resulting in mevalonate-5-
pyrophosphate and adenosine diphosphate (ADP). [8–12] While details 
of the protein motion that occurs during catalysis remain unclear, the 
LID (Fig. 1) region is likely involved in an opening and closing motion 
to permit the binding and release of substrates.[13–15] Herdendorf 
and Miziorko investigated the functional role of conserved basic 
residues in human PMK and suggested that R110 was important for 
human PMK catalysis.[16] R111 and R84 are situated close to the 
“Walker B” motif and seem to be involved in binding M5P.[16] 
Residues K100 and K101 are in close proximity to the ATP binding site, 
and likely stabilize the transition state for conversion of ATP to 
ADP.[17, 18] 
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Fig. 1 Crystal structure of human PMK (PDB ID 3ch4)[22] showing the different 
functionally relevant regions of the protein. The LID region caps the active site where 
phosphate transfer occurs, and contains catalytic residues needed for stabilizing the 
negative charge buildup in the phosphate transfer transition state. The CORE and 
Substrate domains are proposed to participate in significant domain rearrangements 
upon binding the substrates M5P and MgATP.[15]  
In this study, we aim to identify novel inhibitors with high 
affinity for human PMK, based on our understanding of important 
protein-ligand interactions that involve the abovementioned basic 
residues. These inhibitors could provide clues as to the relative 
importance of binding interactions, and could themselves be useful as 
chemical probes of function (ex. in cellular assays or in vivo). 
Molecular docking has become an important early-stage method for 
finding novel inhibitors, when a protein structure is available.[19, 20] 
The process allows a large number of chemicals to be tested quickly in 
silicoand promising chemicals can then be prioritized for experimental 
verification of binding in vitro.[21] Given the high false-positive rate of 
docking predictions, it is crucial to verify predicted binding affinity 
using experimental assays. Two PMK structures have been published, 
allowing for docking-based identification of inhibitors.[2, 22] 
NMR methods allow for a comprehensive monitoring of the 
effects of ligand binding, by providing chemical shift change 
measurements that reflect structural changes throughout the entire 
protein. Of particular interest, the 1H-15N HSQC experiment can 
provide an effective method for monitoring changes to a protein 
structure upon substrate or inhibitor addition, based on changes to 1H 
and 15N chemical shifts of all the protein backbone amides.[23] Since 
PMK is known to undergo substrate-induced structural changes[24], 
solution NMR techniques are well-suited to study interactions involving 
the human PMK/ligand complexes, which may also involve ligand-
induced global structural rearrangements, such as the domain closure 
that substrate binding induces. Using molecular docking, solution NMR 
techniques, and fluorescence titrations, we identified novel inhibitors of 
human PMK. By monitoring 1H-15N HSQC chemical shift perturbations, 
site specific molecular interactions were identified and characterized. 
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Materials and Methods 
Virtual Screening Protocol 
Chemicals to be docked were sourced from two datasets: an in-
house collection of 10,000 drug-like compounds, previously purchased 
or synthesized for kinase and oxidoreductase studies, and 
Chemiebase, a Thai Natural Products collection containing 1,000 
structures.[25, 26] Before docking, ligands were adjusted to the 
proper protonation state at pH 7.4 by Pipeline Pilot, ver. 7.4 [27], and 
three-dimensional structures were calculated using Corina.[28] 
Molecular docking experiments were performed with AutoDock 
4.2.[29–31] 
The structure of human PMK (PDB ID: 3CH4) was obtained from 
the Protein Data Bank.[22] Gasteiger charges and hydrogens were 
added using AutoDock Tools (ADT). The docking grid, centered on the 
M5P binding pocket, was also prepared using ADT with a grid box 
created using 60 × 60 × 60 points and a resolution of 0.375 Å. 
Protein Expression and Purification 
Human PMK is a 192-residue protein with a molecular weight of 
22.0 kDa. To aid in purification, a hexa-histidine tag was added at the 
N-terminus resulting in a total molecular weight of 24.2 kDa. Human 
PMK cDNA was purchased from OriGene, subcloned into the pET15b 
expression plasmid, expressed, and purified as described 
previously.[8] Briefly, the expression plasmid was transformed into 
Escherichia coli BL21 (DE3) Rosetta cells(Novagen) which encoded 
human PMK. Then, cells were grown in 1 L of Luria-Bertani(LB) media 
containing ampicillin (amp) and chloramphenicol (chl) until the optical 
cell densities at 600 nm (OD600) reached 0.7. The cells were harvested 
by centrifugation for 15 minutes at 6000xg. These cells were 
suspended in minimal media with amp-chl antibiotics supplemented 
with 15N-NH4Cl (Sigma Aldrich) as the lone source of nitrogen.[32] 
Cells were allowed to acclimate for an hour, and then they were 
induced with 1 mM IPTG. Cells were harvested 4h after induction by 
centrifugation. Cell pellets were re-suspended in a buffer containing 50 
mM potassium phosphate, 5 mM imidazole, 5% glycerol, 1mM 
phenylmethanesulfonylfluoride (PMSF), and 300 mM NaCl at pH 7.8. 
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Cells were lysed by passage through in a microfluidizer at ~17 kpsi. 
The lysate was clarified by centrifugation at 15,000 rpm for 30 
minutes, and the supernatant loaded onto 1 mL of a Ni-Sepharose 
Fast-Flow resin (GE Healthcare). The column was washed with the 50 
mM phosphate buffer until A280 < 0.005, and the protein was eluted 
using the same buffer supplemented with 300 mM imidazole. Protein 
concentration was determined spectrophotometrically using an 
extinction coefficient (ε280) of 32,290 M−1 cm−1 calculated with ExPASy 
ProtParam and the amino acid sequence.[33] 
NMR Sample Preparation and Spectroscopy 
Protein was concentrated to 400–600 µM by using a 10 kDa 
cutoff centricon (AMD Millipore) filter and exchanged into a buffer 
containing 20 mM potassium phosphate, 5 mM dithiothreitol (DTT), 
100 mM potassium chloride, 10% glycerol, 0.02% sodium azide, and 
10% D2O, at pH 6.5. All screened compounds were dissolved in d6-
dimethyl sulfoxide (DMSO) to a concentration of 5 mM. Titrations were 
performed using 100 µM increments. Spectra were compared to 
control experiments of PMK and d6-DMSO (Supp. Fig. 2). Crosspeaks 
without a d6-DMSO effect 1H-15N HSQC chemical shifts were monitored 
and used to calculate Kd values. NMR experiments were performed at 
25 °C using a Varian 600 MHz NMR system at 599.515 MHz using a 
triple resonance probe, with actively shielded Z-gradients. NMR data 
were processed and visualized by using NMRPipe[34] and analyzed 
with NMRview.[35] Dissociation constants (Kd) were calculated by from 
chemical shift changes resulting from conversion of free PMK, to the 
various bound states, as described previously.[15] The peaks that 
were monitored were in fast exchange in both 1H and 15N dimensions. 
Chemical-shift perturbations from NMR titrations were quantified using 
Eq. 1,  
 
Then, the Kd value was determined by plotting and fitting (GraphPad 
Prism ver. 4.00[36]) the chemical shift changes (Δshiftobs) as a 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Biochemical and Biophysical Research Communications, Vol. 430, No. 1 (January 2013): pg. 313-319. DOI. This article is © 
Elsevier and permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from 
Elsevier. 
8 
 
function of the concentration of protein and ligand, using the quadratic 
equation in Eq. 2, 
 
where L0 and P0 are the total ligand concentration at a particular point 
and protein concentration, respectively, while Δshiftmax is the 
maximum chemical shift change observed for the particular peak of 
interest. 
Fluorescence Titration 
Fluorescence titrations were performed at 25 °C, using a Jasco 
FP-6500 spectrofluorotometer. The fluorescence emission of human 
PMK was measured in a total volume of 0.4 mL of buffer containing 20 
mM potassium phosphate, 5 mM DTT, 100 mM potassium chloride, 
10% glycerol at pH 6.5 and 5 µM human PMK. Excitation was 
performed at 295 nm, and emission was recorded at 300–400 nm. To 
determine the Kdthe difference in intensity between bound and free 
states at each data point were monitored and fitted as a function of 
ligand concentration to the one-site specific binding equation using 
GraphPad Prism ver. 4.00.[36] 
Results 
Chemicals from the two sources (synthetic and natural 
products) were prioritized for experimental screening based upon 
docking scores and cluster size, from Autodock 4.2 virtual screening. 
In total, 26 compounds were identified and then screened using NMR 
1H-15N HSQC titration experiments; and, chemical shift changes were 
monitored upon addition of ligand aliquots. Four of these 26 chemicals 
(15%) showed measurable affinity for PMK in the NMR assay, so 
fluorescence titrations were also performed for these four compounds 
to confirm their binding to PMK. Binding affinities for these 
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experiments are summarized in Table 1 and binding fits are provided 
in Supp. fig. S1 and S2. 
 
Table 1 Predicted and experimental binding affinity for compounds identified using 
Autodock 4.2 to dock compounds into human PMK. NMR and fluorescence techniques 
were then used to experimentally verify binding, and determine dissociation constants 
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(Kd values).                                                                                                              
aThe NMR fit was not reliable because in addition to a specific binding event that 
seems to occur at low concentrations, there is also a non-specific effect that does not 
plateau. 
In an attempt to illustrate the location of inhibitor binding, 
chemical changes were mapped onto the human PMK crystal structure 
(PDB ID: 3ch4). In Figure 2the 2D 1H-15N HSQC spectra and chemical 
shift mapping are shown for 3 the chemicals sourced from the in house 
collection of synthetic compounds. Figure 3 depicts this information for 
the hit obtained from the Chemibase collection of Thai natural 
products. 
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Fig. 2 Chemical shift perturbations due to binding of the inhibitors identified from 
the synthetic compound collection. 1H-15N HSQC spectra chemical shifts are mapped 
onto the human PMK crystal structure [22], with the predicted binding pose from 
Autodock for each ligand; chemical shift changes are color-coded such that red is a 
large (> 0.09 ppm) chemical shift change, yellow is a medium (0.05–0.09 ppm) 
chemical shift change, and blue indicates small or no chemical shift change. Inset 
panels show chemical shift changes that were used to fit binding data (Eq. 1 and Eq. 
2). Panels A and B are for compound CSDDD_1633, C and D are for compound 
CSDDD_2260, and E and F are for compound CSDDD_2419.  
 
Fig. 3 Chemical shift perturbations due to binding of an inhibitor (luteolin) from the 
Thai Natural Products compound collection, Chemiebase.[25, 26]. 1H-15N HSQC 
spectra chemical shifts (Panel B) are mapped onto the human PMK crystal structure 
(Panel A) [22], with the predicted binding pose from Autodock shown; chemical shift 
changes are color-coded such that red is a large (> 0.09 ppm) chemical shift change, 
yellow is a medium (0.05–0.09 ppm) chemical shift change, and blue indicates small 
or no chemical shift change. The inset panel shows chemical shift changes that were 
used to fit binding data (Eq. 1 and Eq. 2).  
Discussion 
The studies presented herein identified four novel inhibitors of 
PMK, which could lead to pharmacologically useful chemical probes or 
perhaps even drug leads that target the mevalonate pathway via 
inhibition of PMK. Molecular docking provided a prioritized listing of 
chemicals with potential affinity for PMK, with chemicals selected from 
two chemical collections, an inhouse collection of synthetic 
compounds, and Chemiebase[25, 26], a Thai natural product 
collection. Hits were identified from each chemical source and 
experimentally validated using NMR 1H-15N HSQC and fluorescence 
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experiments. Of compounds predicted to bind to PMK using Autodock, 
15% were verified by two methods (NMR and fluorescence) as being 
actual ligands for PMK. It is noteworthy that NMR titration methods are 
inherently limited in that they do not provide accurate measures of Kd 
values, when the Kd value is much less than the protein concentration 
that must be used in the experiment (which is itself limited by 
experimental sensitivity of the HSQC experiment). In these situations, 
data fitting to determine Kd must be done using a quadratic equation 
(Eq. 2), and errors increase as Kd≪[protein]. But, NMR chemical shift 
perturbation data will confirm binding and provide an upper limit for a 
Kd even in these situations, and more accurate Kd values can then be 
obtained with fluorescence titrations. 
Docking and subsequent titrations (NMR and fluorescence) 
identified three synthetic compounds from the in-house compound 
collection (CSDDD library) with Kd values in the 12–30 µM range 
(fluorescence), Table 1. A common feature of these compounds is the 
presence of negative charges, which could mimic the negative charge 
on the phosphate groups of the natural substrates, ATP and M5P. 
Indeed, Autodock 4.2 placed these ligands (Fig. 2A, 2C, 2E) near the 
LID and CORE regions of the protein, close to the highly basic region of 
the known binding site for the natural substrates. Likely, these 
inhibitors are taking advantage of the strong electrostatic interactions 
with positively charged amino acids in the vicinity, including K17, R18, 
K19, K22, R138, and R141. Each of the three in-house collection 
inhibitors bind tightly to human PMK (Table 1) and these affinities 
favorably compare to those of the natural substrates ATP (29 ± 6 µM) 
and ADP (19.9 ± 9.0 µM).[15] When plotting the chemical shift 
perturbations for two chemicals (Supp. Fig. S3), complex binding was 
observed that could not be accounted for by the quadratic binding 
model used herein. In the case of CSDDD_2419, (Supp. fig. S3A) the 
binding fit showed a nonspecific effect in addition to an initial binding 
event that appears to be saturable. These additional effects can be 
detected using NMR titrations, because NMR is adept at detecting 
weakly interacting ligands; thus, there is a need for additional 
fluorescence titrations to verify the presence of saturable ligand-
protein binding, and to obtain more accurate Kd values when 
Kd≪[protein]. 
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NMR titrations can also provide structural information, based on 
location of the perturbed amino acid in the 3D structure of the protein, 
which corresponds to the crosspeak that is perturbed (if chemical shift 
assignments are available for the protein). Monitoring of chemical shift 
perturbations of crosspeaks in 2D 1H-15N HSQC spectra of PMK 
indicates there has been substantial movement of residues in the 
CORE and LID regions shown in Fig 2.[15] CSDDD_1633 and 
CSDDD_2260 both perturb the chemical shift of D163, an important 
hinge residue between the LID and CORE regions.[15] Also, ligand-
PMK binding produced chemical shift perturbations outside of the 
binding site, suggesting a conformational changes, such as those that 
could result from motion around the hinge residue between domains, 
as we have reported previously.[15] Similar chemical shift 
perturbations are seen in this study to those that we have reported 
previously for ATP binding, both at the hinge and outside the ATP 
binding site, further suggesting that the in-house synthetic compounds 
are binding similarly to ATP. 
Consistent with their binding in a highly basic pocket (intended 
to accommodate phosphates), all three of the compounds identified 
have at least two formal negative charges, either on sulfonate groups 
(CSDDD_1633 and CSDDD_2419) or carboxylic acids (CSDDD_2260). 
Recently, we observed that molecules with sulfonates could function as 
biomimics for naturally occurring negatively charged ligands with 
phosphates, sulfates, or posttranslationally modified residues (either 
phosphorylated or sulfated).[37] Compounds CSDDD_1633 and 
CSDDD_2419 also contain phenolic groups that would be expected to 
have low pKa’s, based on potential for resonance delocalization of 
negative charge (though an azo group or into a quinine carbonyl). This 
would put an additional negative charge on these molecules. Thus, all 
inhibitors are highly charged, making them suitable mimics of the PMK 
substrates which are also rich with negative charges. 
Docking and subsequent titration studies also identified a 
natural product inhibitor, luteolin, a flavanoid, from the Chemibase 
collection. Luteolin has modest affinity for PMK, with a Kd of 61 µM. 
While it appears that luteolin exhibits no charge, this is probably not 
accurate. As for two of the compounds reported above, luteolin 
contains phenolic groups that are likely to be readily ionized, due to 
resonance delocalization into the quinine carbonyls. Indeed, the 
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phenolic quinone substructure in in CSDDD_1633 is similar to the 
corresponding substructure in luteolin. Chemical shift perturbation 
mapping for this compound (Fig. 3) is strikingly different from the in-
house compounds. It is therefore possible that luteolin is binding 
differently than the in-house synthetic chemicals. But, luteolin does 
cause a large chemical shift perturbation to the active site D163, as 
expected.[15] Interestingly, luteolin has been reported to show a wide 
range of biological effects including cardiovascular protection [38], but 
it is not clear what protein targets are responsible for this effect. It is 
possible that binding to PMK may at least contribute to the favorable 
cardiovascular effects of luteolin. 
Conclusion 
In summary, we have identified novel inhibitors of PMK, which 
possess significant negative charge that is suitable for binding to the 
highly basic PMK active site. Using virtual screening to identify 
potential inhibitors, and NMR and fluorescence experiments to verify 
binding, we found that docking yielded a hit rate of 15% and identifies 
reasonably potent PMK inhibitors with Kd values in the 6–60 µM range. 
These molecules could be useful to investigators as chemical genetic 
probes or as starting points in further drug and inhibitor design 
studies. 
 Highlights 
 Natural and synthetic inhibitors of human phosphomevalonate 
kinase identified. 
 Virtual screening yielded a hit rate of 15%, with inhibitor Kd’s of 
10–60 µM. 
 NMR studies indicate significant protein conformational changes 
upon binding. 
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Supplementary Material 
01 
Supplementary information 
Supplemental Figure Legends 
Supplemental figure S1. Fitting of fluorescence data for ligands 
identified in this study.  Plots are organized as such: CSDDD_1633 is 
panel A, CSDDD_2260 is panel B, CSDDD_2419 is panel C, and 
luteolin is panel D. Data were fitted to the one-site specific binding 
equation in GraphPad Prism ver. 4.00: 
 
Supplemental figure S2. Fitting of data for chemical shift 
perturbation for CSDDD_1633 (panel A) by monitoring G177 and 
CSDDD_2260 (panel B) by monitoring T128.  Lines represent fits to 
the quadratic equation (see equation 2 Materials and Methods). 
Supplemental figure S3. Plots of NMR data for chemical shift 
perturbation of CSDDD_2419 (panel A) and luteolin (panel B).  In 
addition to what may be a saturable binding event at lower 
concentration (highlighted by the boxed regions), there is also a 
nonsaturable effect at higher concentrations – so, NMR titration data 
could not be fitted to the quadratic model used herein. 
Supplemental figure S4.  1H-15N HSQC spectra of PMK upon 
exposure to increasing concentrations of d6-DMSO.  Red peaks are free 
PMK, grey peaks 5% d6-DMSO and black peaks are 10% d6-DMSO. 
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Supplemental Figures 
Supplemental figure S1. 
 
 
Supplemental figure S2. 
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Supplemental figure S3. 
 
 
 
Supplemental figure S4. 
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PMK phosphomevalonate kinase 
M5P mevalonate-5-phosphate 
HSQC heteronuclear single quantum coherence 
1HMG CoA hydroxymethyl glutaryl-CoA reductase 
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